stent

Most read scientific articles of april at solaci.org

The most read scientific articles on interventional cardiology of april

01- Post MI Betablockers for Good? Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long term, provided they do not present cardiac failure or systolic function deterioration.&nbsp; Read more HERE 02- Thrombocytopenia and Thrombosis May Be Linked to AstraZeneca Vaccine, Analysis Reports This is one of the<a href="https://solaci.org/en/2021/05/07/the-most-read-scientific-articles-on-interventional-cardiology-of-april/" title="Read more" >...</a>

Tasa de stroke post cirugía vs angioplastia coronaria en un análisis de más de 10.000 pacientes

How to Discontinue Antiplatelet Therapy Prior Non-Cardiac Surgery

Both the indication and discontinuation of antiplatelet therapy to balance ischemic-bleeding risks has been left to physician criterion.&nbsp; However, leaving the decision to one single specialist might not be the best. This is when the team’s role becomes essential.&nbsp; This study looked at the advantages consensus decision-making amongst clinicians, surgeons and anesthesiologists to continue or<a href="https://solaci.org/en/2021/05/03/how-to-discontinue-antiplatelet-therapy-prior-non-cardiac-surgery/" title="Read more" >...</a>

Bilateral Distal Transradial Access for Chronic Total Occlusion Recanalization and Multivessel Coronary Disease Percutaneous Intervention

[APT Medical Sponsored Clinical Case] Bilateral Distal Transradial Access for Chronic Total Occlusion Recanalization and Multivessel Coronary Disease Percutaneous Intervention

Introduction Chronic total occlusion (CTO) represents the most challenging setting for percutaneous coronary intervention (PCI) and multivessel coronary disease (MCD) is often treated in a staggered manner and in a deferred procedure. Although transfemoral is one of the common access site, the transradial access (TRA) has been used with similar procedural success [1]. The distal<a href="https://solaci.org/en/2021/04/28/apt-medical-sponsored-clinical-case-bilateral-distal-transradial-access-for-chronic-total-occlusion-recanalization-and-multivessel-coronary-disease-percutaneous-intervention/" title="Read more" >...</a>

ticagrelor_enfermedad_vascular_periférica

Back to Basics: Ticagrelor Questioned and Clopidogrel in the Limelight

Yet another observational study has come to question the antiaggregation power of ticagrelor when it comes to death or MI reduction, pointing at its higher risk of bleeding vs. clopidogrel.&nbsp; This new analysis recently published in JAHA includes a large number of patients undergoing acute coronary syndrome (ACS) in the clinical practice.&nbsp; Ticagrelor has been<a href="https://solaci.org/en/2021/04/28/back-to-basics-ticagrelor-questioned-and-clopidogrel-in-the-limelight/" title="Read more" >...</a>

Xience Receives CE Mark for Short and Ultrashort DAPT Schemes

Dual antiplatelet therapy (DAPT) one month after angioplasty with Xience stent was approved in Europe for patients with high risk of bleeding. &nbsp; The CE Mark approval comes after studies Xience&nbsp;28 and Xience&nbsp;90 are published. Immediately after authorization, Abbot was fast to announce what they consider to be the shortest approved scheme with the most<a href="https://solaci.org/en/2021/04/26/xience-receives-ce-mark-for-short-and-ultrashort-dapt-schemes/" title="Read more" >...</a>

duración terapia de doble antiagregación plaquetaria

Dual Antiplatelet Therapy and TAVR: Obsolete Guidelines

The current guidelines recommend dual antiplatelet therapy (DAPT) 3 to 6 months after transcatheter aortic valve replacement (TAVI). Some recent data finally condensed in the present meta-analysis and recently published in JAHA happen to challenge these guidelines.&nbsp; Clinical studies that investigated single antiplatelet therapy versus DAPT until November 2020 were analyzed and divided according to<a href="https://solaci.org/en/2021/04/26/dual-antiplatelet-therapy-and-tavr-obsolete-guidelines/" title="Read more" >...</a>

IVUS vs OCT para guiar la angioplastia ¿Cuál elegir?

IVUS vs OCT to Guide PCI: Which Should We Choose?

Controlling stent expansion with optical coherence tomography (OCT) based on an external elastic membrane–based protocol for stent sizing&nbsp;resulted non-inferior to the control group which used intravascular ultrasound (IVUS) and superior the angiography only group. Based on these study outcomes and the prior outcomes, we should use IVUS imaging if available.&nbsp; There are no specific algorithms<a href="https://solaci.org/en/2021/04/22/ivus-vs-oct-to-guide-pci-which-should-we-choose/" title="Read more" >...</a>

Esquema corto y monoterapia, una práctica llena de evidencia

Short Therapy and Monotherapy, Plenty of Evidence

A short dual antiplatelet therapy (DAPT) of 1 to 3 months followed by P2Y12 inhibitor monotherapy after second generation drug eluting stent (DES) implantation is safer and as effective as the traditional scheme. The idea is clear, but why hasn’t aspirin monotherapy been tested as follow up? Is aspirin old fashioned? Are there physiopathological reasons<a href="https://solaci.org/en/2021/04/12/short-therapy-and-monotherapy-plenty-of-evidence/" title="Read more" >...</a>

The Most Read Articles on Interventional Cardiology of March

The Most Read Articles in Interventional Cardiology of March

01- Surgeons’ Claim on Low-Risk Patients with Aortic Stenosis Recent randomized trials including low-risk patients showed positive results for transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement. Read more HERE 02- Major Cause of Myocardial Injury by COVID-19 The most common cause of myocardial necrosis in patient undergoing COVID-19 infection is microthrombi.&nbsp;These<a href="https://solaci.org/en/2021/04/07/the-most-read-articles-in-interventional-cardiology-of-march/" title="Read more" >...</a>

Lower Mortality with Rechanneling vs. Medical Therapy

We had to wait for it, but we have finally seen a benefit in hard endpoints—such as mortality—derived from rechanneling. Patients with chronic total occlusion (CTO) in whom rechanneling was used as initial strategy showed higher survival rated compared with those receiving medical therapy. As initial treatment strategy, rechanneling a CTO did not show any<a href="https://solaci.org/en/2021/04/07/lower-mortality-with-rechanneling-vs-medical-therapy/" title="Read more" >...</a>

Top